Abstract: Polypeptides which comprise a receptor-ligand pair involved in T-cell activation are disclosed. Nucleic acid molecules encoding the polypeptides, and vectors and host cells for expressing the polypeptides are also disclosed. The polypeptides, or agonists and antagonists thereof, are used to treat T-cell mediated disorders.

Abstract: Polypeptides which comprise a receptor-ligand pair involved in T-cell activation are disclosed. Nucleic acid molecules encoding the polypeptides, and vectors and host cells for expressing the polypeptides are also disclosed. The polypeptides, or agonists and antagonists thereof, are used to treat T-cell mediated disorders.

Abstract: Materials and methods are disclosed for modulating proliferation of cell types associated with Hodgkin's disease through inhibition of IL-13 and components in IL-13 associated signal transduction pathways. Methods to identify inhibitors, compositions comprising the inhibitors, and methods using the inhibitors to treat Hodgkin's disease are also disclosed.

Abstract: The present invention related generally novel mammalian apoptosis-inducing factors, polynucleotides encoding such factors and methods related thereto.

Abstract: Novel Shc-binding protein, oligonucleotides encoding the same, methods of producing and use thereof are disclosed.

Abstract: The invention features substantially pure NRAGE polypeptides. The invention also features substantially pure nucleic acids encoding these polypeptides. The polypeptides and nucleic acids of the invention are useful for therapeutic and diagnostic purposes, and for drug discovery.

Abstract: Novel Shc-binding protein, oligonucleotides encoding the same, methods of producing and use thereof are disclosed.

Abstract: Materials and methods are disclosed for modulating proliferation of cell types associated with Hodgkin's disease through inhibition of IL-13 and components in IL-13 associated signal transduction pathways. Methods to identify inhibitors, compositions comprising the inhibitors, and methods using the inhibitors to treat Hodgkin's disease are also disclosed.

Abstract: Novel Shc-binding protein, oligonucleotides encoding the same, methods of producing and use thereof are disclosed.

Abstract: Disclosed are nucleotide sequences encoding a novel polypeptide termed LSIRF. Also disclosed are methods of preparing the polypeptide and uses thereof.

Abstract: Disclosed are nucleotide sequences encoding a novel polypeptide termed LSIRF. Also disclosed are methods of preparing the polypeptide and uses thereof.

Abstract: Disclosed are nucleic acid molecules encoding polypeptides that specifically bind telomerase RNA. Also disclosed are methods of preparing the nucleic acid molecules and polypeptides, and methods of using these molecules.

Abstract: Disclosed are novel peptides that modulate inflammatory heart disease. Also disclosed are DNA molecules encoding the peptides, and methods of making the peptides.

Abstract: Disclosed are nucleic acid molecules encoding polypeptides that specifically bind telomerase RNA. Also disclosed are methods of preparing the nucleic acid molecules and polypeptides, and methods of using these molecules.

Abstract: Disclosed are novel peptides that modulate inflammatory heart disease. Also disclosed are DNA molecules encoding the peptides, and methods of making the peptides.

Abstract: Disclosed are nucleic acid molecules encoding polypeptides that specifically bind telomerase RNA. Also disclosed are methods of preparing the nucleic acid molecules and polypeptides, and methods of using these molecules.

Abstract: Non-human mammals comprising a disrupted MSH2 gene are disclosed. More particularly, animals having a disruption in one or both alleles of the MSH2 gene or a homolog of the MSH2 gene are disclosed. Animals homozygous for the disruption are viable past the embryonic stage of development but show an increased incidence of lymphoma, intestinal adenomas and carcinomas, and squamous cell tumors of the skin. Specifically disclosed are mice whose genome comprises a disrupted MSH2 gene such that the mice exhibits an increase in the incidence of spontaneous lymphoma over the incidence of spontaneous lymphoma in wild type mice.

Abstract: Disclosed are nucleotide sequences encoding a novel polypeptide termed LSIRF. Also disclosed are methods of preparing the polypeptide and uses thereof.

Abstract: Disclosed is a mouse in which expression of the gene encoding the CTLA-4 receptor is suppressed. Also disclosed is a nucleic acid construct useful in preparing such a mouse, and a cell line containing such construct.